ישראל - עברית - Ministry of Health

takeda israel ltd - icatibant as acetate - תמיסה להזרקה - icatibant as acetate 30 mg / 3 ml - icatibant - icatibant - symptomatic treatment of acute attacks of hereditary angioedima (hae) in adults (with c1 -esterase-inhibitor deficiency).

ישראל - עברית - Ministry of Health

takeda israel ltd - icatibant as acetate - תמיסה להזרקה - icatibant as acetate 30 mg / 3 ml - icatibant

ישראל - עברית - Ministry of Health

teva israel ltd - icatibant as acetate - תמיסה להזרקה - icatibant as acetate 30 mg / 3 ml - icatibant

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - icatibant as acetate - תמיסה להזרקה - icatibant as acetate 10 mg/ml - icatibant

ישראל - עברית - Ministry of Health

csl behring ltd., israel - c - 1 esterase inhibitor human - אבקה להמסה להזרקה\אינפוזיה - c - 1 esterase inhibitor human 500 iu/vial - c1- inhibitor,plasma derived - c1- inhibitor,plasma derived - hereditary angioedema type i and ii (hea) , treatment of acute episodes.

ישראל - עברית - Ministry of Health

kamada ltd, israel - conestat alfa - אבקה להכנת תמיסה לזריקה - conestat alfa 2100 u/vial - conestat alfa

ישראל - עברית - Ministry of Health

teva israel ltd - glatiramer acetate - תמיסה להזרקה - glatiramer acetate 20 mg/ml - glatiramer acetate - glatiramer acetate - for reducing the frequency of relapses in pateints with relapsing-remitting multiple sclerosis. copaxone is indicated for the treatment of patients who have experienced a well defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis (cdms). these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - glatiramer acetate - תמיסה להזרקה - glatiramer acetate 20 mg/dose - glatiramer acetate - glatiramer acetate - for reducing the frequency of relapses in pateints with relapsing-remitting multiple sclerosis. copaxone is indicated for the treatment of patients who have experienced a well defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis (cdms). these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.

ישראל - עברית - Ministry of Health

סביון תעשיות (1987) בע"מ - צוות טכני - to be used for transferring patient from one location or device to another

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - lidocaine as hydrochloride; methylprednisolone acetate - תרחיף להזרקה - lidocaine as hydrochloride 10 mg/ml; methylprednisolone acetate 40 mg/ml - methylprednisolone, combinations - lidocaine - depo-medrol with lidocaine is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - synovitis of osteoarthritis - rheumatoid arthritis - acute and subacute bursitis - acute gouty arthritis - epicondylitis - acute nonspecific tenosynovitis - post-traumatic osteoarthritis.